Meniere Disease
Meniere disease is a chronic inner ear disorder characterized by episodic vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness, attributed to endolymphatic hydrops — pathological distension of the endolymphatic space within the membranous labyrinth. First described by Prosper Meniere in 1861, the condition remains one of the most challenging vestibular diagnoses for neurologists and otologists, both because of its unpredictable clinical course and because of its considerable clinical overlap with vestibular migraine. The treatment algorithm ranges from conservative lifestyle modification to destructive surgical procedures, reflecting the variable severity of the disease.
Bottom Line
- Endolymphatic hydrops: Distension of the endolymphatic space is the pathological hallmark; likely multifactorial etiology involving impaired endolymph absorption
- Diagnostic criteria (AAO-HNS 2020): ≥2 spontaneous vertigo episodes (20 min–12 hours), documented low-to-mid frequency SNHL in the affected ear, and fluctuating aural symptoms (hearing, tinnitus, fullness)
- Most important differential: Vestibular migraine — approximately 30% overlap; key distinction is documented audiometric hearing loss in Meniere disease
- Natural history: Attacks are episodic early on with hearing fluctuation; over years, vertigo may “burn out” but hearing loss becomes permanent and progressive
- Treatment is stepwise: Lifestyle modification → medical therapy → intratympanic injections → surgery; no single treatment is universally effective
- Bilateral disease: Occurs in 25–40% of patients over the disease course, creating management challenges particularly for destructive interventions
Pathophysiology
The histopathologic hallmark of Meniere disease is endolymphatic hydrops — an expansion of the endolymph-filled membranous labyrinth, particularly the cochlear duct and saccule. However, the relationship between hydrops and symptoms is not straightforward: hydrops is found in temporal bones of some asymptomatic individuals, and the degree of hydrops does not always correlate with symptom severity.
Proposed Mechanisms
- Impaired endolymph absorption: Dysfunction of the endolymphatic sac, which normally reabsorbs endolymph, leading to fluid accumulation
- Rupture theory: Distension of the membranous labyrinth may cause microscopic ruptures (e.g., Reissner membrane), allowing potassium-rich endolymph to mix with perilymph, transiently depolarizing and then paralyzing vestibular and cochlear hair cells
- Pressure-mediated dysfunction: Mechanical distortion of the sensory epithelium without frank rupture
- Contributing factors: Genetic susceptibility (familial in ~10%), autoimmune mechanisms, viral infection, anatomic variants of the endolymphatic duct/sac
Epidemiology
- Prevalence: approximately 200 per 100,000
- Peak onset: 40–60 years of age
- Slight female predominance
- Bilateral involvement in 25–40% over disease course (usually develops within 5 years of unilateral onset)
Clinical Presentation
Classic Meniere Attack
The classic Meniere episode consists of four cardinal symptoms occurring together:
The Meniere Tetrad
- Episodic vertigo: Spontaneous rotational vertigo lasting 20 minutes to 12 hours (most attacks last 1–4 hours); severe, often accompanied by nausea and vomiting; the patient is typically incapacitated during an attack
- Fluctuating hearing loss: Initially low-frequency sensorineural hearing loss that recovers between attacks; over time, hearing loss becomes permanent and may extend to all frequencies
- Tinnitus: Low-pitched roaring or buzzing, typically in the affected ear; often increases just before or during an attack
- Aural fullness: A sense of pressure or congestion in the affected ear; may precede vertigo as a warning sign
Disease Stages
| Stage | Vertigo | Hearing | Other Features |
|---|---|---|---|
| Early | Episodic, severe attacks; variable frequency (weekly to yearly) | Low-frequency SNHL; fluctuates; may normalize between attacks | Tinnitus and fullness during attacks; between attacks may feel normal |
| Middle | Attacks may become less severe but more frequent | Hearing loss becomes persistent; less fluctuation; extends to mid frequencies | Chronic tinnitus; persistent imbalance between attacks |
| Late (“Burned out”) | Vertigo attacks diminish or cease; chronic disequilibrium replaces episodic vertigo | Severe-to-profound SNHL; flat audiogram; no fluctuation | Constant tinnitus; chronic imbalance; possible bilateral involvement |
Tumarkin Crisis (Otolithic Crisis of Tumarkin)
Tumarkin crises are sudden drop attacks without loss of consciousness, caused by acute otolith-mediated vestibulospinal dysfunction. The patient describes a sudden sensation of being “pushed” or “thrown” to the ground. These events are unpredictable, cannot be prevented by the patient, and carry significant fall-related injury risk. Tumarkin crises are a late manifestation of Meniere disease and are among the strongest indications for destructive treatment (intratympanic gentamicin or surgery).
Diagnostic Criteria
| Category | AAO-HNS 2020 Criteria |
|---|---|
| Definite Meniere Disease |
|
| Probable Meniere Disease |
|
Differential Diagnosis
Meniere Disease vs Vestibular Migraine
The overlap between Meniere disease and vestibular migraine is the single most challenging diagnostic problem in vestibular medicine. Approximately 30% of patients meet criteria for both conditions, and the two may coexist or one may evolve into the other.
| Feature | Meniere Disease | Vestibular Migraine |
|---|---|---|
| Vertigo duration | 20 min–12 hours | 5 min–72 hours |
| Hearing loss | Low-frequency SNHL, audiometrically documented, fluctuating → progressive | Usually absent; mild fluctuation possible but no progressive SNHL |
| Tinnitus | Low-pitched roaring; lateralized to affected ear; worsens with attacks | May occur; often bilateral; variable character |
| Aural fullness | Present, ipsilateral | May be present; often bilateral |
| Migraine features | Not required (but may coexist) | Headache, photophobia, phonophobia, visual aura (at least some attacks) |
| Audiometry | Low-frequency SNHL (key diagnostic criterion) | Usually normal |
| Response to migraine therapy | Inconsistent | Good response to migraine preventives |
| Progression | Progressive hearing loss over years | No progressive hearing loss |
Other Differential Diagnoses
| Condition | Key Distinguishing Features |
|---|---|
| BPPV | Brief episodes (<60 seconds), triggered by specific positions, no hearing loss, positive Dix-Hallpike |
| Vestibular schwannoma | Gradually progressive unilateral SNHL, tinnitus; vertigo less prominent; MRI shows CPA mass |
| Autoimmune inner ear disease | Bilateral rapidly progressive SNHL (weeks to months); may have systemic autoimmune features; responds to steroids |
| Syphilitic labyrinthitis | Bilateral hearing loss and vertigo; positive treponemal testing; responds to penicillin |
| Perilymphatic fistula | History of trauma or barotrauma; vertigo and hearing loss with straining or pressure changes |
| Superior canal dehiscence | Tullio phenomenon, autophony, conductive hearing loss; CT shows dehiscent superior canal |
| Vestibular paroxysmia | Very brief attacks (seconds to minutes), high frequency (≥30/day), responds to carbamazepine; neurovascular compression of CN VIII |
Diagnostic Workup
Recommended Evaluation for Suspected Meniere Disease
- Pure-tone audiometry: Essential — must document low-to-mid frequency SNHL; serial audiograms to demonstrate fluctuation
- Speech discrimination testing: Disproportionately reduced speech discrimination relative to pure-tone thresholds suggests retrocochlear pathology
- MRI with gadolinium (IAC protocol): To exclude vestibular schwannoma and other CPA lesions; intratympanic gadolinium-enhanced MRI can visualize endolymphatic hydrops directly (research and specialized centers)
- Electrocochleography (ECoG): Elevated SP/AP ratio (>0.40–0.50) supports endolymphatic hydrops; sensitivity ~60–70%
- Vestibular function testing: Caloric testing (canal paresis), vHIT, VEMP — to document vestibular loss and monitor over time
- Autoimmune workup (if bilateral): ESR, CRP, ANA, anti-dsDNA, anti-heat shock protein 70; consider when bilateral SNHL develops rapidly
- Syphilis serology: RPR/VDRL plus confirmatory FTA-ABS; especially in bilateral disease or atypical presentations
Treatment
Management of Meniere disease follows a stepwise approach, progressing from conservative measures to increasingly invasive interventions based on symptom severity and treatment response.
Step 1: Lifestyle Modification
- Sodium restriction: <2 g/day (most widely recommended dietary intervention); rationale is to reduce endolymphatic fluid volume, though evidence base is limited
- Caffeine reduction: May reduce tinnitus and vertigo frequency in some patients
- Alcohol moderation: Alcohol can worsen vertigo acutely
- Stress management: Psychological stress is a common trigger for attacks
- Adequate sleep and hydration: General health optimization
- Trigger avoidance: Patients should maintain a symptom diary to identify individual triggers
Step 2: Medical Therapy
| Medication | Use | Evidence/Notes |
|---|---|---|
| Betahistine | Maintenance prevention (8–48 mg TID) | Widely used outside the US; histamine analog that may improve labyrinthine blood flow; Cochrane review found insufficient evidence of benefit, but individual responses vary; not FDA-approved in the US |
| Diuretics | Maintenance prevention | Hydrochlorothiazide 25 mg + triamterene 37.5 mg daily (Dyazide) is classic combination; theory: reduce endolymph volume; limited RCT evidence but long clinical tradition |
| Vestibular suppressants | Acute attack abortive | Meclizine, dimenhydrinate, or diazepam for acute episodes only; NOT for daily use |
| Antiemetics | Acute attack | Ondansetron, promethazine, or prochlorperazine for nausea/vomiting during attacks |
| Corticosteroids | Acute flares/refractory | Short oral prednisone course for severe flares; limited evidence as preventive |
Step 3: Intratympanic Therapy
Intratympanic injections deliver medication directly to the inner ear through the tympanic membrane, achieving high local concentrations with minimal systemic effects.
| Agent | Mechanism | Vertigo Control | Hearing Risk | Indication |
|---|---|---|---|---|
| Dexamethasone | Anti-inflammatory; may reduce hydrops-related inflammation | Moderate (60–80%) | Minimal — hearing preservation | First-line intratympanic therapy; preferred when hearing preservation is a priority |
| Gentamicin | Selective vestibulotoxicity (chemical labyrinthectomy); destroys vestibular hair cells while partially sparing cochlear cells | Excellent (80–95%) | Significant (20–30% risk of worsening SNHL) | Refractory vertigo when dexamethasone fails; accepted trade-off of hearing risk for vertigo control |
Step 4: Surgical Options
| Procedure | Type | Vertigo Control | Hearing Impact | Notes |
|---|---|---|---|---|
| Endolymphatic sac decompression | Non-destructive | Moderate (60–75%) | Usually preserved | Lowest morbidity; drains or decompresses the endolymphatic sac; efficacy debated (strong placebo effect in sham-controlled trials) |
| Vestibular nerve section | Destructive (selective) | Excellent (90–95%) | Preserved in most | Selectively cuts the vestibular nerve while sparing the cochlear nerve; requires craniotomy; effective but invasive |
| Labyrinthectomy | Destructive (complete) | Excellent (>95%) | Complete hearing loss in that ear | Last resort; reserved for patients with no serviceable hearing in the affected ear; definitively eliminates vertigo |
Bilateral Meniere Disease
Bilateral involvement develops in 25–40% of patients, typically within the first 5 years of unilateral disease onset. Bilateral Meniere disease presents unique management challenges:
- Destructive treatments are contraindicated or must be used with extreme caution: Bilateral vestibular ablation causes permanent oscillopsia and severe imbalance
- Hearing preservation is paramount: Intratympanic dexamethasone is preferred over gentamicin in bilateral disease
- Hearing rehabilitation: Bilateral hearing loss may require hearing aids or, in severe cases, cochlear implantation
- Consider autoimmune etiology: Bilateral Meniere disease should prompt evaluation for autoimmune inner ear disease, which may respond to immunosuppressive therapy
Hearing Rehabilitation
Hearing Management in Meniere Disease
- Hearing aids: Appropriate for mild-to-moderate SNHL; digital hearing aids with directional microphones
- CROS/BiCROS hearing aids: For unilateral severe-to-profound loss with better hearing in the other ear
- Bone-anchored hearing devices: Alternative for unilateral total deafness
- Cochlear implants: For bilateral severe-to-profound SNHL; outcomes in Meniere disease are generally favorable; may also suppress vertigo in some cases
- Assistive listening devices: Amplified telephones, captioning, alerting systems
Prognosis
- Vertigo: Attack frequency is highly variable; approximately 60–80% of patients achieve adequate vertigo control with conservative and medical management; vertigo often “burns out” in late-stage disease
- Hearing: Progressive loss is the rule; average pure-tone loss reaches 50–60 dB over 10–15 years; early aggressive treatment has not been proven to alter hearing trajectory
- Quality of life: Significant impact due to unpredictable attacks, driving restrictions, occupational limitations, anxiety about episodes, and progressive hearing loss
- Psychological impact: High rates of anxiety, depression, and social isolation; screening and treatment of mental health comorbidities is an important component of care
References
- Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Meniere’s Disease. Otolaryngol Head Neck Surg. 2020;162(2_suppl):S1–S55.
- Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Meniere’s disease. J Vestib Res. 2015;25(1):1–7.
- Merchant SN, Adams JC, Nadol JB Jr. Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol. 2005;26(1):74–81.
- Pullens B, van Benthem PP. Intratympanic gentamicin for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2011;(3):CD008234.
- Casani AP, Piaggi P, Cerchiai N, et al. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg. 2012;146(3):430–437.
- James AL, Burton MJ. Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2001;(1):CD001873.
- Harcourt J, Barraclough K, Bronstein AM. Meniere’s disease. BMJ. 2014;349:g6544.
- Sajjadi H, Paparella MM. Meniere’s disease. Lancet. 2008;372(9636):406–414.
- Nabi S, Bhatt NR, Gaskell P, et al. Endolymphatic sac decompression versus intratympanic dexamethasone in the treatment of Meniere’s disease: a systematic review and meta-analysis. Laryngoscope. 2021;131(8):1886–1893.
- Rah YC, Han BI, Park SH, et al. Management of intractable Meniere’s disease after intratympanic injection of gentamicin. Laryngoscope. 2015;125(4):972–978.
- Teggi R, Colombo B, Bernasconi L, et al. Migrainous features in patients with Meniere’s disease. Acta Otolaryngol. 2010;130(5):574–578.
- Rauch SD. Clinical hints and precipitating factors in patients suffering from Meniere’s disease. Otolaryngol Clin North Am. 2010;43(5):1011–1017.
- Thorpe MA, Fagan PA, Taylor J. The natural history of Meniere’s disease. Otol Neurotol. 2020;41(1):122–130.
- Thai-Van H, Bounaix MJ, Fraysse B. Meniere’s disease: pathophysiology and treatment. Drugs. 2001;61(8):1089–1102.
- Nakashima T, Pyyko I, Arroll MA, et al. Meniere’s disease. Nat Rev Dis Primers. 2016;2:16028.